Welcome to our dedicated page for Waters news (Ticker: WAT), a resource for investors and traders seeking the latest updates and insights on Waters stock.
Waters Corporation reports recurring developments across life sciences and diagnostics, including analytical instruments, informatics, service, and high-volume testing workflows. News for WAT commonly covers operating results and guidance, the Analytical Sciences Division, and the Biosciences and Diagnostic Solutions businesses added through the completed BD transaction.
Company updates also include product launches for liquid chromatography, UPLC and UHPLC workflows, MALS detection, rheometry, LC columns, and TA Instruments technologies. Diagnostic news includes FDA-related developments for the Onclarity HPV Self-Collection Kit and BD Onclarity HPV Assay, along with commercial, conference, and shareholder-related updates.
WAT Medical introduces ObeEnd, a revolutionary weight management wristband supported by clinical evidence. The device aims to address the global obesity epidemic by providing a drug-free, effective solution. ObeEnd utilizes neuromodulation technology to reduce caloric intake and enhance post-exercise recovery, showing promising results in clinical studies. The groundbreaking innovation marks a major milestone in the field of weight management.
Waters announced the release of the ACQUITY QDa II Mass Detector, a cost-effective, energy-efficient instrument that enhances compound identification through mass analysis. The new detector offers a 20% increase in mass range, up to 70% lower energy consumption, and is recognized for sustainability by My Green Lab.
Waters (NYSE: WAT) reported first-quarter 2024 financial results with sales of $637 million, a 7% decline, but at the high end of guidance. GAAP EPS was $1.72, well above guidance, with non-GAAP EPS of $2.21. Operational excellence led to gross margin expansion. Full-year guidance maintained for -0.5% to +1.5% organic constant currency sales growth and non-GAAP EPS of $11.75 to $12.05.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.